Estimation of the SARS-CoV-2 infection fatality rate in Germany

T. Dimpfl, J. Sönksen, I. Bechmann, J. Grammig
{"title":"Estimation of the SARS-CoV-2 infection fatality rate in Germany","authors":"T. Dimpfl, J. Sönksen, I. Bechmann, J. Grammig","doi":"10.1101/2021.01.26.21250507","DOIUrl":null,"url":null,"abstract":"Assessing the infection fatality rate (IFR) of SARS-CoV-2 is one of the most controversial issues during the pandemic. Due to asymptomatic or mild courses of COVID-19, many infections remain undetected. Reported case fatality rates - COVID-19-associated deaths divided by number of detected infections - are therefore poor estimates of the IFR. Endogenous changes of the population at risk of a SARS-CoV-2 infection, changing test practices and an improved understanding of the pathogenesis of COVID-19 further exacerbate the estimation of the IFR. Here, we propose a strategy to estimate the IFR of SARS-CoV-2 in Germany that combines official data on reported cases and fatalities supplied by the Robert Koch Institute (RKI) with data from seroepidemiological studies in two infection hotspots, the Austrian town Ischgl and the German municipality Gangelt, respectively. For this purpose, we use the law of total probability to derive an approximate formula for the IFR that is based on a set of assumptions regarding data quality and test specificity and sensitivity. The resulting estimate of the IFR in Germany of 0.83% (95% CI: [0.69%; 0.98%]) that is based on a combination of the RKI and Ischgl data is notably higher than the IFR estimate reported in the Gangelt study (0.36% [0.29%; 0.45%]). It is closer to the consolidated estimate based on a meta-analysis (0.68% [0.53%; 0.82%]), where the difference can be explained by Germany's disadvantageous age structure. Virus mutations, vaccination strategies, and improved therapy will necessitate a re-estimation of the IFR. The proposed method is able to account for such developments.","PeriodicalId":318714,"journal":{"name":"Human Health & Disease eJournal","volume":"46 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Health & Disease eJournal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2021.01.26.21250507","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Assessing the infection fatality rate (IFR) of SARS-CoV-2 is one of the most controversial issues during the pandemic. Due to asymptomatic or mild courses of COVID-19, many infections remain undetected. Reported case fatality rates - COVID-19-associated deaths divided by number of detected infections - are therefore poor estimates of the IFR. Endogenous changes of the population at risk of a SARS-CoV-2 infection, changing test practices and an improved understanding of the pathogenesis of COVID-19 further exacerbate the estimation of the IFR. Here, we propose a strategy to estimate the IFR of SARS-CoV-2 in Germany that combines official data on reported cases and fatalities supplied by the Robert Koch Institute (RKI) with data from seroepidemiological studies in two infection hotspots, the Austrian town Ischgl and the German municipality Gangelt, respectively. For this purpose, we use the law of total probability to derive an approximate formula for the IFR that is based on a set of assumptions regarding data quality and test specificity and sensitivity. The resulting estimate of the IFR in Germany of 0.83% (95% CI: [0.69%; 0.98%]) that is based on a combination of the RKI and Ischgl data is notably higher than the IFR estimate reported in the Gangelt study (0.36% [0.29%; 0.45%]). It is closer to the consolidated estimate based on a meta-analysis (0.68% [0.53%; 0.82%]), where the difference can be explained by Germany's disadvantageous age structure. Virus mutations, vaccination strategies, and improved therapy will necessitate a re-estimation of the IFR. The proposed method is able to account for such developments.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
德国SARS-CoV-2感染致死率估计
评估SARS-CoV-2的感染致死率(IFR)是疫情期间最具争议的问题之一。由于COVID-19的无症状或轻度病程,许多感染仍未被发现。因此,报告的病死率——与covid -19相关的死亡人数除以发现的感染人数——是对IFR的不准确估计。SARS-CoV-2感染风险人群的内源性变化、检测方法的改变以及对COVID-19发病机制的进一步了解进一步加剧了IFR的估计。在这里,我们提出了一种估计德国SARS-CoV-2的IFR的策略,该策略将罗伯特·科赫研究所(RKI)提供的报告病例和死亡人数的官方数据与两个感染热点(奥地利城镇Ischgl和德国城市Gangelt)的血清流行病学研究数据相结合。为此,我们使用总概率定律推导出IFR的近似公式,该公式基于一组关于数据质量和测试特异性和敏感性的假设。结果估计德国IFR为0.83% (95% CI: [0.69%;0.98%]),明显高于Gangelt研究报告的IFR估计值(0.36% [0.29%;0.45%)。它更接近基于荟萃分析的综合估计(0.68% [0.53%;0.82%]),这种差异可以用德国不利的年龄结构来解释。病毒突变、疫苗接种策略和改进的治疗将需要重新估计IFR。所提议的方法能够解释这种发展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Improvement of the Quality of Life by Catheter Ablation for Atrial Fibrillation in Patients Undergoing Hemodialysis Estimation of the SARS-CoV-2 infection fatality rate in Germany Socioeconomic Inequalities in Body Mass Index in Barcelona 1986-2016: An Unconditional Quantile Regression Approach Biodegradable Nanoplatforms with the Multiple Modulation of Tumor Microenvironment for Enhanced Sonodynamic Therapy Cobalt Oxide Nanoparticle-Synergized Strategy Manipulating Autophagy, Ubiquitin-Proteasome and Photothermal Therapy for Enhanced Anticancer Therapeutics
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1